About Kiadis Pharma
Kiadis Pharma is a Healthcare company based in Amsterdam (Netherlands) founded in 1997, and was acquired by Sanofi in November 2020. Therapeutic solutions for hematopoietic stem cell transplants are developed. Kiadis Pharma has raised $32.95 million across 11 funding rounds from investors including Sanofi, Kreos Capital and Life Sciences Partners. Kiadis Pharma has completed 1 acquisition, including Cyto-Sen Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer.
Company details
Founded in 1997 and based in Amsterdam, Netherlands, Kiadis Pharma operates in the biotechnology sector, focusing on solutions for complications in hematopoietic stem cell transplants for blood cancer patients. Allodepleted T-cell immunotherapeutics (ATIR) are utilized to bolster the patients immune system post-transplant, facilitating acceptance from haploidentical or lower-matched donors. Investigations into ATIR applications for leukemia and thalassemia are ongoing.
- Headquarters Amsterdam, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website kiadis.com
- Social LinkedIn X
- Acquired by Sanofi (Nov 2020)
Funding Insights of Kiadis Pharma
Kiadis Pharma has successfully raised a total of $32.95M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.86 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.95M
- Total Rounds 11
- Last Round Post-IPO — $5.86M
- First Round $20.18M
(Jun 2007)
- Investors Count 7
Latest 10 of 11 funding rounds of Kiadis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $5.86M | Post-IPO | – | – | |
| Apr 2020 | $5.43M | Post-IPO | – | – | |
| Apr 2020 | $13M | Post-IPO | – | – | – |
| May 2019 | $31.22M | Post-IPO | – | – | – |
| Oct 2018 | $36M | Post-IPO | – | – | – |
| Aug 2018 | $23.42M | Debt – Venture | – | – | |
| Mar 2018 | $28.83M | Post-IPO | – | – | – |
| Aug 2017 | $17.6M | Debt – Venture | – | – | |
| Jun 2017 | $5.6M | Post-IPO | – | – | – |
| Nov 2012 | $12.77M | Series B | – | – |
8 investors in total: 8 institutional.
Investors in Kiadis Pharma
Kiadis Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, Kreos Capital and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Growth-stage life sciences and tech companies in Europe are funded. | 1998 | questforgrowth.com | Leuven, Belgium | |
Stage agnostic VC firm investing globally | 2004 | draperesprit.com | London, United Kingdom | |
Venture capital is provided to medical life sciences companies. | medsciencescapital.com | The Hague, Netherlands | ||
Management consulting and business management services are provided to clients. | 2007 | nvnom.com | Groningen, Netherlands | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Kiadis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kiadis Pharma
Kiadis Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cyto-Sen Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
NK cell therapies are developed for acute myeloid leukemia treatment. | cytosen.com | Orlando, United States | 2014 | Apr 2019 | •••• |
Complete acquisition details for Kiadis Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Kiadis Pharma
6 dated milestones of Kiadis Pharma across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Kiadis Pharma is founded.
- Funding First funding round of $20.2M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Cyto-Sen Therapeutics.
- Funding Latest funding round, Post-IPO, of $5.9M.
- Exit Acquired by Sanofi.
Web traffic of Kiadis Pharma
Websites that share an audience with Kiadis Pharma (kiadis.com).
Websites whose visitors overlap most with Kiadis Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| viedoc.com | 98% | 21.5K | #713,207 | View details | |
| oxfordimmunotec.com | 64% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kiadis Pharma
Complete news archive for Kiadis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kiadis Pharma
Kiadis Pharma was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Kiadis Pharma is headquartered in Amsterdam, Netherlands.
Kiadis Pharma is a funded company, having raised a total of $32.95M across 11 funding rounds to date. The company's 1st funding round was a Series B of $12.77M, raised on Jun 2007.
Founded in 1997 and based in Amsterdam, Netherlands, Kiadis Pharma operates in the biotechnology sector, focusing on solutions for complications in hematopoietic stem cell transplants for blood cancer patients. Allodepleted T-cell immunotherapeutics (ATIR) are utilized to bolster the patients immune system post-transplant, facilitating acceptance from haploidentical or lower-matched donors. Investigations into ATIR applications for leukemia and thalassemia are ongoing.
Kiadis Pharma has made 1 acquisition, including Cyto-Sen Therapeutics.
Kiadis Pharma has 8 investors. Key investors include Sanofi, Kreos Capital, Life Sciences Partners, NVNOM, and Draper Esprit.
Yes. Kiadis Pharma was acquired by Sanofi in November 2020.